Viracta Therapeutics (VIRX) Net Income by Year
Viracta Therapeutics Inc reported a net loss of $51.1M in fiscal year 2023. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2023 through Q3 FY2024, the same line adds up to a $43.3M net loss. The table below carries 15 fiscal years, from 2009 to 2023, and the quarters Viracta Therapeutics Inc has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
VIRX Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing | FY17Filing | FY16Filing | FY15Filing | FY14Filing | FY13Filing | FY12Filing | FY11Filing | FY10Filing | FY09Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$43.3M | -$51.1Mn/m | -$49.2Mn/m | -$114.8Mn/m | -$19.0Mn/m | -$13.6Mn/m | -$26.6Mn/m | -$35.5Mn/m | -$38.0Mn/m | -$36.7Mn/m | -$43.0Mn/m | -$34.6Mn/m | -$44.0Mn/m | -$20.1Mn/m | -$24.6Mn/m | -$40.2M |
TTM is the trailing twelve months, Q4 FY2023 through Q3 FY2024, summed from the four most recent quarterly filings.
VIRX Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Viracta Therapeutics Inc financials
Frequently Asked Questions
Viracta Therapeutics Inc reported a net loss of $51.1M in fiscal year 2023.
Viracta Therapeutics Inc (VIRX) reported a $49.2M net loss in fiscal year 2022 and a $51.1M net loss in fiscal year 2023. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Viracta Therapeutics Inc (VIRX) reported a $43.3M net loss over the trailing 12 months, Q4 FY2023 through Q3 FY2024, summed from the four most recent quarterly filings.
Across the 15 fiscal years this page covers, Viracta Therapeutics Inc (VIRX) net income went from -$40.2M in fiscal year 2009 to -$51.1M in fiscal year 2023.
Viracta Therapeutics Inc (VIRX) reported -$10.6M in net income in Q3 2024. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Viracta Therapeutics Inc (VIRX) reported on that line in every period on record.